25,543 Shares in Biogen Inc. $BIIB Acquired by Fluent Financial LLC

Fluent Financial LLC bought a new position in shares of Biogen Inc. (NASDAQ:BIIB) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund bought 25,543 shares of the biotechnology company’s stock, valued at approximately $3,578,000. Biogen comprises about 1.4% of Fluent Financial LLC’s portfolio, making the stock its 23rd biggest holding.

Other large investors have also recently modified their holdings of the company. Norges Bank bought a new stake in shares of Biogen in the second quarter worth $284,358,000. AQR Capital Management LLC raised its position in Biogen by 153.6% during the 1st quarter. AQR Capital Management LLC now owns 1,368,842 shares of the biotechnology company’s stock worth $187,258,000 after purchasing an additional 829,150 shares during the last quarter. Orion Porfolio Solutions LLC lifted its holdings in Biogen by 6,828.4% during the 2nd quarter. Orion Porfolio Solutions LLC now owns 517,275 shares of the biotechnology company’s stock worth $64,965,000 after buying an additional 509,809 shares during the period. Arrowstreet Capital Limited Partnership grew its position in shares of Biogen by 190.7% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 624,371 shares of the biotechnology company’s stock valued at $78,415,000 after buying an additional 409,591 shares during the last quarter. Finally, AustralianSuper Pty Ltd increased its stake in shares of Biogen by 85.9% in the second quarter. AustralianSuper Pty Ltd now owns 739,416 shares of the biotechnology company’s stock valued at $92,863,000 after buying an additional 341,719 shares during the period. Institutional investors own 87.93% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently commented on BIIB. Jefferies Financial Group lifted their price objective on Biogen from $190.00 to $210.00 and gave the stock a “buy” rating in a research note on Friday, November 28th. Morgan Stanley boosted their price target on shares of Biogen from $149.00 to $156.00 and gave the stock an “equal weight” rating in a research report on Friday, December 12th. Mizuho increased their price objective on shares of Biogen from $169.00 to $177.00 and gave the stock an “outperform” rating in a research report on Monday, November 3rd. Sanford C. Bernstein lifted their target price on shares of Biogen from $155.00 to $157.00 and gave the stock a “market perform” rating in a research note on Monday, November 3rd. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Biogen in a research report on Monday, December 15th. Ten investment analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $183.08.

Biogen Stock Up 2.9%

Biogen stock opened at $174.80 on Friday. The company has a market capitalization of $25.64 billion, a PE ratio of 15.93, a PEG ratio of 1.47 and a beta of 0.13. Biogen Inc. has a 12-month low of $110.04 and a 12-month high of $185.17. The firm’s fifty day moving average is $163.65 and its 200 day moving average is $145.29. The company has a quick ratio of 2.04, a current ratio of 2.72 and a debt-to-equity ratio of 0.35.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings results on Thursday, October 30th. The biotechnology company reported $4.81 EPS for the quarter, topping analysts’ consensus estimates of $3.89 by $0.92. Biogen had a net margin of 15.98% and a return on equity of 14.13%. The business had revenue of $2.53 billion during the quarter, compared to analysts’ expectations of $2.34 billion. During the same period last year, the company posted $4.08 earnings per share. The business’s quarterly revenue was up 2.8% on a year-over-year basis. Biogen has set its FY 2025 guidance at 14.500-15.00 EPS. As a group, sell-side analysts predict that Biogen Inc. will post 15.83 EPS for the current fiscal year.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.